CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −120 | $323.14 | $39K | 31,854 |
| 2026-11-02 | Reardon Andrew CLO & Secretary | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,000 | 24,104 | ||
| 2026-11-02 | Aryeh Jason Director | Sale | −700 | $320.43 | $224K | 108,758 |
| 2026-10-30 | Aryeh Jason Director | Sale | −50 | $317.74 | $16K | 110,819 |
| 2026-10-30 | Aryeh Jason Director | Sale | −50 | $318.23 | $16K | 110,769 |
| 2026-10-30 | Aryeh Jason Director | Sale | −52 | $320.24 | $17K | 110,717 |
| 2026-10-30 | Aryeh Jason Director | Sale | −1,209 | $320.42 | $387K | 109,508 |
| 2026-10-30 | Aryeh Jason Director | Sale | −50 | $320.49 | $16K | 109,458 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Option exercise 10b5-1 | +340 | $52.27 | $18K | 36,854 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −833 | $302.51 | $252K | 36,021 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,976 | $303.54 | $600K | 34,045 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,535 | $304.52 | $467K | 32,510 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −404 | $306.18 | $124K | 32,106 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −235 | $307.19 | $72K | 31,871 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −17 | $307.74 | $5K | 31,854 |
| 2026-10-02 | Reardon Andrew CLO & Secretary | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −340 | 29,104 | ||
| 2026-09-22 | Zimmermann Martine Director | Shares withheld for taxes | −115 | $298.50 | $34K | 3,782 |
| 2026-09-10 | Zimmermann Martine Director | Sale | −1,200 | $285.00 | $342K | 3,897 |
| 2026-09-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −300 | $283.99 | $85K | 41,214 |
| 2026-09-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,800 | $285.17 | $513K | 39,414 |
Page 2 of 43 · 858 trades